Although established in controlled studies that there is no advantage to 4-drug highly active antiretroviral therapy (HAART) or regimens with or without protease inhibitors (PIs), we questioned this finding in a clinical setting (ie, no inclusion criteria). Ours is a single clinic retrospective study including all participants >18 years of age during their first year of HAART. A total of 190 participants were reviewed, with 168 (88%) attaining a viral load <400 copies/mL at the end of a year of HAART; 144 of 164 (88%) succeeded with 3 drugs and 24 of 26 (92%) with 4 drugs (P ¼ .51). In all, 59 of 71 (83%) succeeded using a PI versus 109 of 119 (92%) without a PI (P ¼ .08). Male gender and exposure time to HAART were significant variables for a successful outcome. Failures were due to side effects (50%), nonadherence (45%), and drug allergy (5%). Our results support current guidelines recommending 3-drug HAART.
Introduction
For more than a decade, combination therapy with 3 effective agents has been the accepted means to treat HIV-1 infection. 1 Highly active antiretroviral therapy (HAART) consisting of combinations of 3 antiretroviral (ARV) drugs from up to 3 different groups (ie, nucleoside reverse transcriptase inhibitor [NRTI] , nonnucleoside reverse transcriptase inhibitor [NNRTI] , and protease inhibitor [PI]) have reduced morbidity and mortality from HIV infections since its introduction into clinical use. 2 However, since the first HIV-1 treatment trials, there have been concerns that the existence of resistance to at least one of the agents prior to initiating HAART would predestine failure. Genotyping of a participant's virus before starting HARRT was not uniformly recommended until recently, thus now removing the concern over preexisting resistance. 3 Other concerns include lack of adherence and the patient stopping one of the medications abruptly because of intolerance or allergy. We noticed that in our clinic, some physicians often elected to start 4 agents rather than 3 for the reasons mentioned. The results of the AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double-blind, placebo-controlled study comparing 2 NRTIs þ an NNRTI versus 3 NRTIs þ an NNRTI as initial HARRT, showed no advantage to the 4-drug regimen and concluded that there were no significant differences between the 3-drug and 4-drug regimens. 4 We asked similar questions but in a clinical setting without any inclusion and exclusion criteria and compared 3-drug versus 4-drug regimens with or without the use of a PI. We took the opportunity to review outcomes after the first year of therapy to assess whether any additional benefits could be associated with 4drug regimens. The amount of drug resistance during this period of time could only be assessed by 29 available genotypes that found no major resistance markers. Our objectives were (1) to compare the percentage of participants with a successful outcome (ie, viral load <400 copies/mL after 1 year) using 3-drug versus 4-drug regimens, (2) to compare the percentage of successful outcomes of PI-based versus non-PIbased regimens, and (3) to determine reasons for failure.
University of Kentucky HIV Clinic (i.e., Bluegrass Care Clinic) during the spring of 2008. We collected data on participants who started HAART anytime after 1998 up to summer 2007. Only participants aged 18 years and older at the time of first HAART were included. We reviewed more than 600 participant records and found 220 participants who started HAART after 1998. Participants with <8 months of data were excluded. A total of 190 (ie, 86%) participants took their initial HAART for a period of at least 8 months and these participants were included in the analysis. Ritonavir (RTV)-boosted PI treatment was considered a single agent.
Primary Outcome
We counted as successful participants those with viral loads <400 copies/mL after at least 8 months of HAART or up to 16 months if no earlier results were available. A minimum of 8 months was selected for 2 reasons: time to undetectable HIV viral load ranges in treatment-naive patients from 12 to 24 weeks and patients were examined every 3 to 4 months. If the participants changed their regimen after 8 months but before the end of 1 year, the viral load and CD4 count at the time of the change in therapy was used for the calculations. Exposure time is the time in months that the patient took the same ARV medications.
Statistical Methods
Descriptive statistics were performed to describe characteristics of all groups (3 medications, 4 medications, with PI, and without PI; Tables 1 and 2 ). Continuous variables were described with means and standard deviations. Categorical variables were summarized with counts and percentages. Age was categorized as 18 to 29, 30 to 49, and 50 years. Chi-square tests of independence were used to compare the demographic and laboratory characteristics for 3-versus 4-medication groups with and without PIs (Tables 1-3). A subgroup analysis was performed based on initial CD4 counts ( Figures 1 and 2 ). Baseline CD4 count (cells/mm 3 ) was categorized into 3 groups (<200, 200-399, 400) and trends of changes in CD4 counts were plotted for the 3-medication group, 4-medication group, PI group, and non-PI group (Figure 3 ). Multiple logistic regression models were performed to control for age, gender, race, smoking, alcohol, exposure time, and baseline CD4 count, and HIV-1 viral load ( Table 4 ). The variables selected are the ones thought to be associated with successful outcomes. [5] [6] [7] [8] [9] Comparison between groups were assessed at a 5% significant level (P < .05). All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, North Carolina).
Results

Demographic and Laboratory Characteristics
The study population consisted of 190 HIV-1-infected patients taking their first HAART. In all, 164 (86%) were taking 3 medications including 65 using PIs, while 26 (14%) were taking 4 medications including 6 using PIs. Demographic and laboratory characteristics comparing 3-versus 4-medication groups are shown in Table 1 . A total of 48% of the participants had AIDS, 43% consumed alcohol, and 49% were smokers. There were no significant differences between age, gender, smoking, and alcohol use in participants taking 3 versus 4 medications. There were more Caucasians in the 3-medication group (P < .05). A total of 56 different HAART regimens were used, with Combivir and efavirenz (EFV, 35 participants), atripla (23), Trizivir (13), Combivir and nevirapine (NVP, 11), and Truvada and norvir-boosted atazanavir (ATV, 10), the 5 leading 3-drug combinations. Trizivir and EFV (5), Trizivir and tenofovir (TDF, 5), Trizivir and NVP (3), Trizivir and ATV (3), and Atripla and zidovudine (ZDV, 2), the 5 leading 4-drug combinations. In addition to these agents, other agents used were stavudine (d4T), emtricitabine (FTC), lamivudine (3TC), didanosine (ddI), abacavir (ABC), delavirdine (DLV), indinavir (IDV), RTV (full dose), lopinavir/ritonavir (LPV/r), saquinavir (SQV), nelfinavir (NFV), and amprenavir (APV). Regimens with more than 1 failure included Trizivir (4 of 13 failed), Combivir and EFV (3 of 35 failed), Combivir and NFV (2 of 7 failed), and ddI with d4T and IDV (2 of 3 failed).
The median baseline HIV-1 viral load in the 3-and 4-medication groups were 46 756 copies/mL and 43 565 copies/mL, respectively. The median baseline CD4 count was 207 cells/mm 3 (3 drugs) versus 219 cells/mm 3 (4 drugs). The mean baseline CD4 counts of patients taking 3 and 4 medications were 258 and 251 cells/mm 3 , respectively (P > .05). Table 2 describes the demographic and laboratory characteristics and comparison of PI versus non-PI groups. In all, 19 of 32 (59%) females were taking a PI, while only 52 of 158 (33%) males were taking a PI (odds ratio [OR] 2.9, 95% confidence interval [CI] 1.32-6.33, P ¼ .004). There were no differences between groups in the number of alcohol beverage users, or those with insurance coverage. The median baseline HIV-1 viral load in the PI and the non-PI groups was 41 724 copies/mL and 52 000 copies/mL, respectively. The median baseline CD4 count was 227 cells/mm 3 (PI) versus 210 cells/mm 3 (no PI). The mean baseline CD4 counts of patients taking PIs and not taking PIs were 273 cells/mm 3 and 248 cells/mm 3 , respectively (P > .05).
Primary Outcome
Of the 190 patients, 168 (88%) attained a viral load <400 copies/mL at the end of 1 year of HAART, including 144 of 164 (88%) that used 3 drugs and 24 of 26 (92%) that used 4 drugs successfully (P ¼ .51). A total of 59 of 71 (83%) who used a PI succeeded versus 109 of 119 (92%) who did not use a PI (P ¼ .08). There was no significant difference in the primary outcome when comparing PI versus non-PI patients and 3-versus 4-medication groups. Females failed more often, 25% versus 9% (Table 3 ; P < .001). There were no significant differences between success and failure in the number of smokers, alcoholic beverage users, or those with insurance coverage. Success stratified by baseline CD4 counts with subclassifications of viral load and number of medications or use of PIs did not show any significant differences (Figures 1 and 2) .
Rises in CD4 counts were seen in all 4 cohorts: 3 drugs 171 + 13 (mean + SEM), 4 drugs 221 + 50, PI 148 + 22, and no PI 196 + 17. Figure 3 shows the CD4 changes from baseline for CD4 <200, 200-399, and 400 cells/mm 3 for each of the 4 cohorts. Comparing rises for each of the 3 groups within each cohort and cohort to its comparator, there were no significant differences in the amount of increase in CD4 counts except for a smaller rise in CD4 count when comparing CD4 <200 cells/ mm 3 to 200-399 cells/mm 3 within the 3-drug group and within the no PI group. There were no significant differences in the success rate when examining only those with a baseline viral load >100 000, 86% when taking 3 drugs, 96% when taking 4 drugs, 88% when taking a PI, and 90% with no PI. Multiple logistic regression analysis identified 2 significant variables for a successful outcome, male gender and exposure time, that is, the time the patients took medicine ( Table 4 ). The average exposure time for patients taking 3 and 4 medications were 11.7 months and 11.4 months, respectively, and for patients taking PI and non-PI regimens were 11.5 months and 11.8 months, respectively. There were no significant differences in the average exposure time for 3-versus 4-medication (P ¼ .44) groups and PI versus non-PI groups (P ¼ .34). In the multivariate analysis, the longer the exposure time, the better were the chances of a successful outcome (P < .001).
Causes of Failure
There were a total of 22 participants who had a viral load 400 copies/mL, at the end of a year. The most common reason for failure was side effects (50%), followed by nonadherence (45%) and drug allergy (rash) in 1 patient (5%). Side effects included bone marrow suppression in 7 participants and gastrointestinal symptoms (nausea, vomiting) in 4 participants. Of the 11 participants who failed due to side effects, only 2 participants took 4 drugs and 6 participants took PIs.
Discussion
This study makes 2 important comparisons with the primary outcome being <400 copies/mL after 1 year: (a) initial HAART using 3 or 4 drugs without any further characterization of how many agents from each therapeutic class of agent, and (b) initial HAART with or without a PI, without any restriction of the number of agents used (ie, either 3 or 4). There were no inclusion or exclusion criteria other than that our participants were all >18 years of age as our clinic cares mostly for adults. Choice of HAART was based only on assessment of the participant by his or her clinic physician. A major limitation to this study is that the data are from only 1 clinic, with 9 physicians initiating treatment for their patients. In addition, the clinic serves both inner city and rural populations almost equally. Most patient demographics were not significantly different between groups; however, the OR suggested some possible trends.
Unexplainably, we noted more females were taking PIs (59%) than were males (33%; P ¼ .004), with females having Baseline VL <100 000 copies/mL; n = 34, n* = 32
Baseline VL ≥100 000 copies/mL; n = 58, n* = 53 P = .63 P = .07 P = .57 P = .11 P = NA Figure 1 . Subgroups analysis for CD4 counts <200. Baseline indicates at the start of therapy; n ¼ number of participants; n* ¼ number of participants succeeded (end viral load <400 copies/mL) in that particular group; NA ¼ not applicable; PI ¼ protease inhibitor; VL¼ HIV-1 viral load. a 3 times greater odds of taking PI (95% CI 1.32-6.33). It is likely that certain non-PI HIV therapies were avoided in females due to possible teratogenicity. The odds of drinking alcoholic beverages for patients taking a PI is 1.6 times (95% CI 0.93-3.06) compared with patients not taking a PI (P ¼ .08). There were no significant differences among gender based on the number of medications, but the odds of males being on 3 drugs was 1.2 times (95% CI 0.4-3.5). Overall, we had significantly more females failing to obtain a viral load <400 copies/ mL with males being 3.4 times (95% CI 1.3-9.04) more successful. This was not seen by Moore et al who reviewed the records of 2547 patients, of which 20% were females and found no significant differences in the proportion of females and males taking PIs or in the outcome. 10 We have noticed in our clinic that women who were not prescribed HAART were >3 times more likely to miss patient appointments than women who were taking HAART (Jana Collins, MS in Family Studies, 2008. ''Factors Effecting Medical Appointment Adherence of HIV Positive Patients,'' unpublished thesis). Gordillo et al report that poor adherence to HAART has been associated with intravenous drug users (IVDUs), younger individuals, participants with depression, and those who lacked self-perceived social support. 11 We have no evidence whether this is the case in our clinic. However, we have observed such issues as spousal abuse and child-care responsibilities as reasons mentioned for female noncompliance. We found no significant differences in the primary outcome between the 3-drug regimen and the 4-drug regimen and for treatment with or without a PI. Our results support those reported in the ACTG A5095 study, 4 as well as in current guidelines. However, the odds of success for the 4medication group were 1.6 times that of the 3-medication group and the odds of success for non-PI group were 2.2 times that of the PI group. The OR suggests that with larger cohorts, there might be differences in successful outcome favoring the extra drug in HAART or a non-PI combination. Interestingly, ACTG A5142 study examined the use of EFV or LPV/r plus 2 NRTIs for initial therapy and found virologic failure less likely in the EFV group than in the LPV/r group. 12 However, a large clinical trial in treatment-naive patients, ACTG A5095, found no significant differences between 3-drug and 4-drug regimens. However this trial did not include PIs in either treatment group. 4 Success stratified by baseline CD4 counts with subclassifications of viral load and number of medications or use of PIs did not show any significant differences between groups. There were no significant differences in primary outcome when a PI was included for patients with baseline CD4 counts < 200 cells/mm 3 . Rises in CD4 counts were seen in all 4 cohorts.
Baseline VL <100 000 copies/mL; n = 54, n* = 45
Baseline VL ≥100 000 copies/mL; n = 44, n* = 38 Comparing rises for each of the 3 groups within each cohort and cohort to its comparator, there were no significant differences in the amount of increase in CD4 counts except for a smaller rise in CD4 count when comparing CD4 <200 cells/mm 3 to 200-399 cells/mm 3 within the 3-drug group and within the no PI group. In each of these groups, the greatest increase in CD4 counts occurred for those with 200 to 400 cells/mm 3 initially. The significant differences were not large and no more than marginally clinically relevant and possibly relate to the limitations of the study. There were 22 participants who failed to achieve a viral load <400 copies/mL at the end of 1 year. We identified 29 patients who had genotyping testing prior to starting HAART and did not find any major resistance mutations. We suspect that our failures did not represent failure of HAART but rather issues with adherence, drug tolerability, or drug allergy. There was no significant difference in the number of failures between the cohorts.
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